KalVista Pharmaceuticals, Inc. (KALV)
26.77
-0.04
(-0.15%)
USD |
NASDAQ |
May 21, 16:00
26.78
+0.01
(+0.04%)
After-Hours: 19:59
KalVista Pharmaceuticals Research and Development Expense (TTM) : 48.42M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Intellia Therapeutics, Inc. | 351.67M |
| Recursion Pharmaceuticals, Inc. | 382.53M |
| Sensei Biotherapeutics, Inc. | 13.28M |
| Tango Therapeutics, Inc. | 127.14M |
| BioCryst Pharmaceuticals, Inc. | 187.06M |